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Abstract 
 
Background: Radiofrequency ablation (RFA) is commonly used to locally treat 
hepatocellular carcinoma (HCC). However, when tumors are close to the Glisson’s 
capsule, RFA may induce injury in this region, complicating therapeutic efforts. We 
investigated the impact of RFA-induced Glisson’s capsule-associated complications on 
liver function and prognosis of HCC patients. 
Methods: We retrospectively reviewed our patient database and found 170 early-stage 
HCC patients treated via RFA from April 2004 to December 2012. We defined RFA-
induced Glisson’s capsule-associated complication as lasting hepatic arterioportal (AP) 
fistula, major intrahepatic bile-duct dilatation (affecting two or more subsegments), or 
hepatic infarction. We also defined liver failure as initial occurrence of either total 
bilirubin increase (>3.0 mg/dL), uncontrolled ascites, or encephalopathy. 
Results: In our cohort, 15 patients had RFA-induced Glisson’s capsule-associated 
complications (incidence of related complications, with some overlap: lasting AP fistula, 
n = 9; major intrahepatic bile-duct dilatation, n = 7; and hepatic infarction, n = 2). The 
cumulative incidence of liver failure before stage progression was significantly higher 
and the median overall survival (OS) was significantly lower (52.3 months) in HCC 
patients with Glisson’s capsule-associated complications than in those without Glisson’s 
capsule-associated complications (95.0 months). In addition, multivariate analysis 
demonstrated that Glisson’s capsule-associated complication was a significant 
independent factor associated with OS. 
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Conclusions: In this study, we have shown that early-stage HCC patients with RFA-
induced Glisson’s capsule-associated complications may have higher risks in poor 
prognosis.   
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Introduction 
 
Approximately 700,000 people annually die due to hepatocellular carcinoma (HCC), and 
HCC is the third most common cause of cancer mortality [1]. Radiofrequency ablation 
(RFA) is frequently used for the local treatment of HCC [2-4]. It is the best treatment 
alternative in patients with early-stage HCC who are not eligible for surgical resection. 
RFA extends survival by >60 months [5]. 
 A cohort study including 1,170 HCC patients reported an RFA complication rate 
of 2.2% and a mortality rate of 0.003% [5]. In addition, a recent review of 34 studies 
showed that major complications and mortality rate was 4.1% and 0.15%, respectively 
[6]. However, the contribution of RFA-related complications to HCC patient survival is 
unclear. 
The Glisson’s capsule extends into the liver as sheaths around the hepatic bile-ducts, 
hepatic arteries, and portal veins. HCC lesions adjacent to the Glisson’s capsule may be 
affected by RFA, thus increasing the risk of complications such as intrahepatic bile-duct 
dilatation, hepatic arterioportal (AP) fistula, and hepatic infarction. Most of these 
complications are irreversible and may negatively affect liver function and prognosis. In 
other cancers, postoperative complications significantly diminish patient survival [7-9]. 
To our knowledge, only few reports have analyzed the long-term outcomes of RFA-
related complications [10]. The aim of this study was to retrospectively evaluate the 
prognostic impact of RFA-induced Glisson’s capsule-associated complications in patients 
with early-stage HCC.  
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Patients and Methods 
Patients 
This study was approved by the Research Ethics Committees of Graduate School of 
Medicine, Chiba University (approval number 2,246). Informed consents of examinations 
and treatments were obtained from all of patients included in this study according to the 
policy of our institution. Patient records/information were anonymized and de-identified 
prior to analysis. 
Medical records were retrieved for HCC patients treated at our institution. Patients 
enrolled in this study were selected using the following inclusion criteria at their initial 
RFA: (1) the presence of histologically confirmed or clinically diagnosed HCC; (2) 
presence of early-stage HCC (single hypervascular ≤50 mm HCC lesion or ≤3 
hypervascular ≤30 mm HCC lesions without macrovascular invasion or extrahepatic 
metastasis); and (3) Child–Pugh A or B. We excluded patients using the following 
criteria: (1) no hypervascular HCC, (2) no contrast-enhanced computed tomography (CT) 
or magnetic resonance imaging (MRI) after >3 months of initial RFA treatment, or (3) 
liver-unrelated death within a year. 
 
RFA 
Treatment strategies in our institution are based on the Japanese guidelines [11]. First, we 
investigated whether definitive treatment can be accomplished by surgical resection or 
whether RFA is an alternative to surgical resection. RFA was performed as described 
previously [12]. Briefly, the procedures were performed under real-time ultrasound 
guidance (Power Vision 8000, Aplio XV, Aplio XG, or Aplio 500; Toshiba, Tokyo, 
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Japan) and a 17-gauge cooled-tip electrode (Cool-Tip; RF Ablation System, Covidien, 
Boulder, Colombia, CO). Under conscious sedation, an electrode was inserted and 
radiofrequency was delivered for 6–15 min for each lesion. As appropriate, intrapleural 
or intraperitoneal fluid infusion was performed before electrode insertion. We evaluated 
effectiveness via dynamic CT or MRI on the day after RFA. The treatment assessments 
were performed as published previously [12]. To judge if ablation was complete or not, 
we compared images taken before and after ablation. The definition of completely ablated 
was as follows: post-ablation CT or MRI indicated a non-enhanced area covering the 
lesion where the tumor was located prior to ablation, outlined with a safety margin in the 
surrounding liver parenchyma. 
 
Follow-up, assessment of complications, and definition of RFA-induced 
Glisson’s capsule-associated complication 
During follow-up, tumor markers, including α-fetoprotein (AFP) and des-γ-carboxy 
prothrombin, were measured every 1–2 months, and dynamic CT or MRI was performed 
every 4–6 months. To evaluate complications, all patient CT or MRI images and medical 
records obtained from just before initial RFA to additional HCC treatment or last follow-
up were reviewed by 2 hepatologists (T. W. and S.O. with 7 and 12 years of experience, 
respectively). We defined RFA-induced Glisson’s capsule-associated complication as (1) 
lasting AP fistula that persisted for >3 months, (2) major intrahepatic bile-duct dilatation 
(affecting two or more subsegments), or (3) hepatic infarction. 
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Statistical analysis   
Demographic and clinical characteristics, the rate of RFA-induced Glisson’s capsule-
associated complications in each subsegment, and the proportion of cause of death were 
compared by the chi-square test or Fisher’s exact test, as appropriate. Univariate and 
multivariate logistic regression analyses were used to estimate the odds ratios for risk 
factors of RFA-induced Glisson’s capsule-associated complications per nodules. 
Perivascular HCC was defined as a tumor located <5 mm from the first-order or second-
order branches of portal veins, intrahepatic arteries, or bile-ducts based on the previous 
study [13]. Kaplan-Meier plots were used to estimate cumulative liver failure before stage 
progression and overall survival (OS). Cumulative liver failure before stage progression 
was measured from the date of initial RFA until the onset date of liver failure, which was 
defined as initial occurrence of either total bilirubin increase (>3.0 mg/dL), uncontrolled 
ascites, or encephalopathy. The censoring date was defined as the last date of radiological 
follow-up before stage progression. OS was measured from the date of initial ablation 
until the date of death. The censoring date was defined as the date of last follow-up. 
Univariate and multivariate Cox proportional-hazard models were used to estimate the 
hazard ratios for risk factor predicting cumulative liver failure before stage 
progression and OS. P values of <0.05 was considered statistically significant. All 
statistical analyses were performed using the SPSS statistical software (v. 23; SPSS-IBM, 
Chicago, IL, USA). 
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Results 
Patients’ characteristics 
Of 235 patients who received RFA for initial HCC treatment between April 2004 and 
December 2012, 170 were eligible for inclusion in the present study (Fig 1). Sixty-five 
patients were excluded for the following reasons: 35 were not at the early stage, 22 lacked 
typical hypervascular HCC, 6 had no radiological assessment after ≥3 months of initial 
RFA, and 2 died of liver-unrelated disease within a year. The baseline characteristics of 
our eligible patients are summarized in Table 1. Median age was 74 years, and the most 
frequent etiology was hepatitis C virus (HCV, 76.5%), followed by hepatitis B virus 
(HBV, 7.1%).  The median maximum tumor size was 19 mm (range, 6.5–42 mm), and 
129 patients (75.9%) had a single tumor. One hundred and fifty-two patients were Child–
Pugh A (89.4%) and the remaining were Child–Pugh B. Tumor size and liver function 
were similar to data in recent studies from Japan [14,15]. Procedural rate for HCC 
treatment was 1.35 (one procedure: 110 patients; two procedures: 60 patients). There was 
no significant difference between patients with and without RFA-induced Glisson’s 
capsule-associated complications. 
 
Fig 1. Study Flow 
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Table 1. Baseline characteristics. 
 
 
Abbreviations: HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; 
AFP, α-fetoprotein. 
  
Variables All cases 
With RFA-
induced 
Glisson’s 
capsule-
associated 
complications 
Without RFA-
induced 
Glisson’s 
capsule-
associated 
complications 
P  
Gender [n (%)]     
 Male 114 (67.1) 11 (73.3) 103 (66.5) 0.776 
 Female 56 (32.9) 4 (26.7) 52 (33.5)  
Age [n (%)]     
 ≤74 years 92 (54.1) 10 (66.7) 82 (52.9) 0.307 
 >74 years 78 (45.9) 5 (33.3) 73 (47.1)  
Child–Pugh class [n (%)]     
 A 152 (89.4) 14 (93.3) 138 (89.0) 0.510 
 B 18 (10.6) 1 (6.7) 17 (11.0)  
HBs-Ag positive [n (%)]     
 Absent 158 (92.9) 14 (93.3) 144 (92.9) 0.714 
 Present 12 (7.1) 1 (6.7) 11(7.1)  
HCV-Ab positive [n (%)]     
 Absent 40 (23.5) 4 (26.7) 36 (23.2) 0.488 
 Present 130 (76.5) 11 (73.3) 119 (76.8)  
Alcohol abuse [n (%)]     
 Absent 156 (91.8) 13 (86.7) 143 (92.3) 0.356 
 Present 14 (8.2) 2 (13.3) 12 (7.7)  
Maximum tumor size [n 
(%)] 
    
 ≤20 mm 96 (56.5) 9 (60.0) 87 (56.1) 0.773 
 >20 mm 74 (43.5) 6 (40.0) 68 (43.9)  
Number of liver tumors 
[n (%)] 
    
 Single 129 (75.9) 11 (73.3) 118 (76.1) 0.511 
 Multiple 41 (24.1) 4 (26.7) 37 (23.9)  
AFP [n (%)]     
 ≤100 ng/mL 142 (83.5) 12 (80.0) 130 (83.9) 0.463 
 >100 ng/mL 28 (16.5) 3 (20.0) 25 (16.1)  
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RFA-induced Glisson’s capsule-associated complications in study 
patients 
In this study, AP fistula, intrahepatic bile-duct dilatation, and hepatic infarction due to 
initial RFA developed in 17 patients (10.0%), 14 patients (8.2%), and 2 patients (1.2%), 
respectively (Table 2). Fig 2 shows typical cases of AP fistula (A), hepatic infarction (B), 
and bile-duct dilatation (C) after RFA in HCC patients. Of the 17 patients who had AP 
fistula, 8 patients had transient AP fistulae and 9 patients had lasting AP fistulae, which 
were radiologically observed for 3 months or more after initial RFA. There were 7 patients 
with minor intrahepatic bile-duct dilatation (limited to one subsegment) and 7 patients 
with major intrahepatic bile-duct dilatation (affected two or more subsegments).  
The details of 15 patients with RFA-induced Glisson’s capsule-associated 
complications according to the definition of this study are shown in Table 3. Three 
patients observed both intrahepatic bile-duct dilatation and AP fistula. Two of nine 
patients with lasting AP fistulae had fistulae distant from the ablation zone. Of the 7 
patients with major intrahepatic bile-duct dilatations, 3 and 2 showed liver failure before 
stage progression and partial shrinkages of liver volume, respectively. Of the 9 patients 
with lasting AP fistulae, 3 had liver failure before stage progression. Partial shrinkages of 
liver volume were observed in 2 patients with liver infarctions. 
 
Fig 2. Typical cases of AP fistula (A), hepatic infarction (B), and bile-duct dilatation 
(C) after RFA in HCC patients. (A) A 66-year-old male with hepatic AP fistula after 
RFA for HCC in subsegment 8. Right: 8 months after RFA (Patient 12 in Table 3); (B) a 
63-year-old female with liver infarction after RFA for HCC in subsegment 3. Middle: the 
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next day of RFA. Right: 15 months after RFA (Patient 10 in Table 3); (C) a 68-year-old 
male with bile-duct dilatation in 2 subsegments and liver abscess after RFA for HCC in 
subsegment 4. C1: before RFA. C2: 4 months after RFA. C3: 2 years after RFA (Patient 
11 in Table 3). White arrows show treated tumors and white arrowheads show RFA-
induced Glisson’s capsule-associated complications.   
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Table 2. Complications related to RFA in HCC patients. 
 
 
Abbreviations: AP, arterioportal; AV, arteriovenous  
Complications N (%) 
AP fistula 17 (10.0) 
 Transient 8 (4.7) 
 Lasting 9 (5.3) 
Intrahepatic bile-duct dilatation  14 (8.2) 
 Minor 7 (4.1) 
 Major 7 (4.1) 
Portal vein thrombosis 5 (2.9) 
Intra-abdominal hemorrhage 4 (2.4) 
Hepatic infarction 2 (1.2) 
Pleural hemorrhage 2 (1.2) 
Hemobilia 1 (0.6) 
Hepatic abscess 1 (0.6) 
Nearby organ injury 1 (0.6) 
Dissemination 1 (0.6) 
AV fistula (transient) 1 (0.6) 
 14 
Table 3. Patient list of RFA-induced Glisson’s capsule-associated complication in HCC patients. 
   
Patients Age Gender 
Maximum 
tumor 
size 
(mm) 
Tumor 
number 
Tumor 
location 
(subsegment) 
Type of RFA-induced Glisson’s 
capsule-associated complication 
Positional relation 
between ablation 
zone of tumor and 
Glisson's capsule-
associated 
complication 
Partial 
shrinkage 
of liver 
Cause of liver 
failure before 
stage 
progression 
Cause of 
death Bile-duct 
dilatation 
AP 
fistula 
Liver 
infarction 
1 74 F 15 1 S3 − − + Nearby + − Other disease 
2 83 M 22 1 S3 + − − Nearby − − HCC 
3 66 M 21 1 S8 − + − Distant − 
Hepatic 
encephalopathy 
Liver 
dysfunction 
4 82 M 30 2 S8, S6 + − − Nearby − − 
Liver 
dysfunction 
5 67 M 20 1 S7 + + − Nearby − Jaundice HCC 
6 70 M 19 1 S8 − + − Nearby − − HCC 
7 76 M 18 1 S4 − + − Nearby − − HCC 
8 76 M 20 1 S4 + + − Nearby + − Alive 
9 63 M 23 2 S6, S7 − + − Nearby − Ascites Alive 
10 63 F 12 2 S3, S5 − − + Nearby + − Alive 
11 68 M 21 1 S4 + − − Nearby + Ascites 
Liver 
dysfunction 
12 66 M 13 1 S8 − + − Nearby − − Alive 
13 72 F 18 2 S6, S8 − + − Distant − − Alive 
14 72 M 24 1 S4 + − − Nearby − 
Hepatic 
encephalopathy 
Alive 
15 75 F 12 1 S8 + + − Nearby − − 
Liver 
dysfunction 
 
Abbreviations: F, female; M, male; S, segment; HCC, hepatocellular carcinoma; AP, arterioportal  
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Impact of RFA-induced Glisson’s capsule-associated complications in 
HCC patients 
S1 Table shows the rate of RFA-induced Glisson’s capsule-associated complication in 
each subsegment. Although there was no significant difference between subsegments, the 
incidences of Glisson’s capsule-associated complications were frequently observed in 
subsegment 3 and 4 (subsegment 3: 15.0%, subsegment 4: 15.4%). We analyzed the 
impact of risk factors of RFA-induced Glisson’s capsule-associated complications. In 
multivariate analysis, location of tumor defined as perivascular in this study (tumors 
located <5 mm from first-order or second-order branches of portal veins, intrahepatic 
arteries, or bile-ducts) was significant risk factor for RFA-induced Glisson’s capsule-
associated complications (S2 Table). 
Fig 3 shows Kaplan–Meier plots of cumulative liver failure before stage progression. 
Patients with RFA-induced Glisson’s capsule-associated complications had significantly 
higher incidence of liver failure before stage progression than those without Glisson’s 
capsule-associated complications (P = 0.003). Multivariate analysis indicated that 
Glisson’s capsule-associated complication was an independent risk factor for liver failure 
before stage progression as well as Child–Pugh B (Table 4).  
During the study period, 55 of 170 patients died (median follow-up: 46.7 months). 
Recurrence-free survival was not significantly different between patients with and 
without RFA-induced Glisson’s capsule-associated complications (P = 0.365).  The 
median OS was significantly worse in patients with RFA-induced Glisson’s capsule-
associated complications than in patients lacking Glisson’s capsule-associated 
complications [52.3 months (95% CI: 34.4–71.7) vs. 95.0 months (95% CI: 73.5–116.5), 
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P = 0.021, Fig 4]. The forest plot indicated that RFA-induced Glisson’s capsule-
associated complication significantly correlated with a poor prognosis compared with 
other complications (Fig 5). Multivariate analysis showed that RFA-induced Glisson’s 
capsule-associated complication was a significant independent factor linked to a poor 
prognosis as well as being HCV-Ab positive (Table 5). We also analyzed cause of death 
in patients with and without RFA-induced Glisson’s capsule-associated complications. 
The rate of the death due to liver dysfunction was significantly higher in patients with 
RFA-induced Glisson’s capsule-associated complications than in patients without 
Glisson’s capsule-associated complications (26.6% vs. 6.5%, P <0.001). 
 
Fig 3. Cumulative incidence of liver failure before stage progression in RFA-treated 
patients. 
 
Fig 4. Overall survival in RFA-treated HCC patients. 
 
Fig 5. The forest plots according to complications related to RFA in HCC patients. 
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Table 4. Univariate and multivariate analysis of cumulative liver failure before stage 
progression in RFA-treated HCC patients. 
 
Variables 
Univariate analysis 
P 
Multivariate analysis 
P Hazard 
ratio 
95% CI 
Hazard 
ratio 
95% CI 
Gender, male 2.384 0.684–8.303 0.172    
Age, >74 years 0.439 0.142–1.355 0.152    
HBs-Ag positive 0.451 0.058–3.472 0.444    
HCV-Ab positive 0.867 0.304–2.466 0.788    
Alcohol abuse 1.336 0.305–5.851 0.701    
Child–Pugh B 14.364 5.508–37.461 <0.001 27.263 8.567–86.761 <0.001 
Tumor size and 
number, >20 mm, 
multiple 
1.721 0.606–4.890 0.308    
AFP, > 100 ng/mL 0.662 0.151–2.902 0.585    
RFA-induced 
Glisson’s capsule-
associated 
complication 
4.360 1.534–12.389 <0.001 11.711 3.310–41.438 <0.001 
Complications 
except RFA-
induced Glisson’s 
capsule-associated 
complication 
1.567 0.449-5.470 0.481    
 
Abbreviations: HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; 
AFP, α-fetoprotein 
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Table 5. Univariate and multivariate analysis of survival in RFA-treated patients with 
HCC 
 
Variables 
Univariate analysis 
P 
Multivariate analysis 
P Hazard 
ratio 
95% CI 
Hazard 
ratio 
95% CI 
Gender, male 1.188 0.670–
2.108 
0.556    
Age, >74 years 1.547 0.910–
2.633 
0.107    
HBs-Ag positive 0.378 0.092–
1.555 
0.178    
HCV-Ab positive 2,878 1.232–
6.724 
0.015 2.840 1.216–
6.636 
0.016 
Alcohol abuse 0.751 0.271–
2.082 
0.581    
Child–Pugh B 1.209 0.545–
2.683 
0.640    
Tumor size and 
number, >20mm, 
Multiple 
1.300 0.745–
2.267 
0.356    
AFP, > 100 ng/mL 1.021 0.513–
2.034 
0.952    
RFA-induced 
Glisson’s capsule-
associated 
complication 
2.300 1.120–
4.722 
0.023 2.247 1.094–
4.613 
0.027 
Complications except 
RFA-induced 
Glisson’s capsule-
associated 
complication 
0.948 0.426-
2.106 
0.895    
 
Abbreviations: HBs-Ag: Hepatitis B surface antigen, HCV-Ab: Hepatitis C virus antibody, 
AFP: α-fetoprotein.  
 19 
Discussion 
In this study, we aimed to assess the effect of RFA-induced Glisson’s capsule-associated 
complication on HCC prognosis. Our results show that HCC patients with RFA-induced 
Glisson’s capsule-associated complications are at a higher risk for liver failure and a poor 
prognosis compared with patients without Glisson’s capsule-associated complications. 
 It is well known that lasting AP fistula develops portal hypertension and causes 
several typical hepatic symptoms such as ascites and varices [16, 17]. Fig 5 indicates that 
lasting AP fistula was strongly correlated with a poor prognosis compared with transient 
AP fistula. Kondo et al. reported that major intrahepatic bile-duct dilatation due to RFA 
was the cause of decreased albumin and increased bilirubin and poor prognosis in HCC 
patients [10]. This study also noted that minor intrahepatic bile-duct dilatation did not 
affect HCC prognosis, a finding corroborated in our study (Fig 5). Hepatic infarction has 
been shown to occur when hepatic arterial and portal vein flow are both compromised, 
leading to segmental liver necrosis and failure [18].  
 In our study, almost half of our patients with AP fistulae after RFA possessed 
unrecoverable fistulae. AP fistula occurs secondary to percutaneous liver procedures, 
such as liver biopsy, transhepatic bile-duct drainage, and RFA [19-22]. However, to the 
best of our knowledge, AP fistula wasn’t included as a complication due to RFA in 
previous studies [6, 23-24]. This might be because they highlighted complications 
immediately after RFA. Our study reviewed not only radiological assessments 
immediately after RFA but also follow-up examinations. Thus, we could rigorously 
evaluate the landscape of AP fistulae in relation to RFA. Our study also noted that AP 
fistulae occur not only adjacent to, but also distantly from the tumor, and importantly, AP 
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fistulae seem to develop due to either or both sticking electrodes directly and terminal 
energy at the time of ablation. A previous report indicated that the rates of minor and 
major bile-duct dilatation were 11.9% and 3.6%, respectively [10]. These rates were in 
agreement with our results. Additionally, other RFA complications such as liver abscess, 
and dissemination were similar to previous studies [23-25].  
 In this study, we selected RFA-induced Glisson’s capsule-associated 
complications as noted above, although they did not necessarily cover all possible 
complications. Portal vein thrombosis, intra-abdominal hemorrhage, hemobilia, and 
arteriovenous (AV) fistula were excluded from this analysis for the following reasons. 
First, one previous study reported that RFA-related portal vein thrombosis is rarely 
progressive with little influence on liver function [26]. Second, intra-abdominal 
hemorrhage, hemobilia and AV fistula were transient and asymptomatic and required no 
additional treatment such as blood transfusion in the patients analyzed in this study.  
As progressive disease affects liver function in HCC patients, it is difficult to tease 
out and dissect the cause of liver failure. We assessed the cumulative incidence of liver 
failure before HCC stage progression and found that early-stage patients with RFA-
induced Glisson’s capsule-associated complications had significant deterioration of liver 
function. Thus, this method of analysis clearly showed the impact of Glisson’s capsule-
associated complication on liver function  
 Shifting the focus on the effect of RFA-induced Glisson’s capsule-associated 
complication on HCC prognosis and survival has shed new light on technical gaps in the 
execution of RFA. Herein, we have demonstrated the dire consequences of such a 
Glisson’s capsule-associated complication. In addition, our study highlights the 
importance of enhancing efforts to avoid RFA-induced Glisson’s capsule-associated 
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complication when conducting RFA. Prophylactic cooling of the bile-duct during RFA 
via intraductal perfusion of saline or 5% dextrose and use of an endoscopic nasobiliary 
drainage (ENBD) tube has been shown to decrease the incidence of biliary injuries [27-
31] Although ENBD tube usage carries risks of complications, such as bleeding, 
gastrointestinal perforation, and pancreatitis, this may be a viable option to decrease the 
chances of RFA-induced Glisson’s capsule-associated complications. However, 
development of techniques that will drastically decrease RFA-induced Glisson’s capsule-
associated complications without introducing other kinds of complications is expected.  
In conclusion, early-stage HCC patients with RFA-induced Glisson’s capsule-
associated complications may have higher risks in poor prognosis. Until there are more 
effective alternative therapies, clinicians performing RFA should ensure proper technique 
when cauterizing tumors to mitigate the risk of Glisson’s capsule-associated 
complications.  
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S1 Table. The rate of RFA-induced Glisson’s capsule-associated complication in 
each subsegment. 
 
 
Abbreviations: RFA, radiofrequency ablation; S, subsegment. 
  
Subsegment 
of the liver 
With RFA-induced 
Glisson’s capsule-
associated complication 
(n = 15) 
Without RFA-induced 
Glisson’s capsule-
associated complication 
(n = 197) 
P  
S1 [n (%)] 0  0  
0.137 
S2 [n (%)] 0 (0) 11 (100) 
S3 [n (%)] 3 (15.0) 17 (85) 
S4 [n (%)] 4 (15.4) 22 (84.6) 
S5 [n (%)] 0 (0) 32 (100) 
S6 [n (%)] 1 (2.7) 36 (97.3) 
S7 [n (%)] 2 (6.7) 28 (93.3) 
S8 [n (%)] 5 (8.9) 51 (91.1) 
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S2 Table. Univariate and multivariate analysis of risk factor for RFA-induced 
Glisson’s capsule-associated complication per tumor. 
 
Variables 
Univariate analysis 
P 
Multivariate analysis 
P Odds 
ratio 
95% CI 
Odds 
ratio 
95% CI 
Gender, male 1.438 0.441–4.688 0.546    
Age, >74 years 0.542 0.179–1.644 0.279    
HBs-Ag positive 0.871 0.107–7.087 0.898    
HCV-Ab positive 0.880 0.268–2.892 0.833    
Alcohol abuse 2.022 0.414–9.864 0.384    
Child–Pugh B 0.571 0.72–4.558 0.597    
Tumor size, >20 
mm 
0.886 0.304–2.585 0.825    
AFP, >100 ng/mL 1.206 0.323–4.505 0.781    
S1 – – –    
S2 0.000 0.000– 0.999    
S3 2.662 0.684–
10.364 
0.158    
S4 2.909 0.853–9.925 0.088    
S5 0.000 0.000– 0.999    
S6 0.280 0.041–2.524 0.321    
S7 0.897 0.192–4.182 0.889    
S8 1.441 0.470–4.416 0.552    
Location, 
perivascular 
3.636 1.049–
12.600 
0.042 3.636 1.049-
12.600 
0.042 
 
Abbreviations: HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; 
AFP, α-fetoprotein; S, subsegment. 
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